SLC5A2 and hydrops fetalis: Novel pharmacological agents such as ARNI (Angiotensin Receptor-Neprilysin Inhibitor), SGLT2 (Sodium-Glucose Cotransporter-2) inhibitors, and sGC (soluble Guanylate Cyclase) stimulators have shown promising results in HF treatment, with their applications continually expanding [2–5].